DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
KEY PRODUCTS
Reset all filters
01 1Dr. Reddy's Laboratories
Reset all filters
01 1EMPAGLIFLOZIN (PRODUCT CODE: EGF8)
Reset all filters
01 1India
Reset all filters
01 1Active
Reset all filters
01 1Complete
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2024-06-28
Pay. Date : 2024-06-25
DMF Number : 36928
Submission : 2022-03-31
Status : Active
Type : II
20
Dr Reddys Laboratories Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
One of their notable products is EMPAGLIFLOZIN (PRODUCT CODE: EGF8), with a corresponding US DMF Number 36928.
Remarkably, this DMF maintains an Active status since its submission on March 31, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 28, 2024, and payment made on June 25, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II